TearClear has initiated a phase 3 trial evaluating TC-002, a preservative-free latanoprost ophthalmic solution, in patients with glaucoma, according to a press release.
The prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, 3-month CLEAR study is investigating the ocular hypotensive efficacy and safety of TC-002 (preservative-free latanoprost ophthalmic solution 0.005%) compared with latanoprost ophthalmic solution 0.005%.
“Enrolling the first subjects is an important milestone,” Stuart Raetzman, CEO of TearClear, said in the release. “We